A5049716608- CRISPR and Genetic Engineering
- Pluripotent Stem Cells Research
- RNA Interference and Gene Delivery
- Cardiac Fibrosis and Remodeling
- Congenital heart defects research
- Mesenchymal stem cell research
- Advancements in Transdermal Drug Delivery
- Animal Genetics and Reproduction
- Toxin Mechanisms and Immunotoxins
- Cardiac Ischemia and Reperfusion
Mayo Clinic in Arizona
2022-2024
The objective of the current study is to develop a new method for tracking transplanted human induced pluripotent stem cells-derived cardiomyocytes (hiPSC-CMs) using magnetic resonance imaging (MRI). CRISPR/dCas9 activation system employed overexpress ferritin heavy chain (FHC) in hiPSC-CMs. mRNA and protein expression FHC hiPSC hiPSC-CMs significantly increased after transfection. Iron chloride does not affect cell viability concentration range from 0 2000 µm. hiPSCs overexpressing (hiPSC-
Heart disease continues to be the leading cause of death globally, even with development and implementation numerous pharmacological surgical treatments. Transplanting cardiomyocytes derived from human-induced pluripotent stem cells (hiPSC-CMs) shows potential for repairing heart damage. However, tracking quantifying these after transplantation in large animals remains challenging. This study aimed develop a hiPSC line that overexpresses ferritin heavy chain (FHC) enable transplanted...
Introduction: Transplantation of human induced pluripotent stem cells-derived cardiomyocytes (hiPSC-CMs) emerges as a promising approach for the treatment heart diseases. However, it is an unmet challenge to precisely localize hiPSC-CMs upon transplantation and quantify graft size in live large animals. To address this issue, we established new track grafted CMs animals using magnetic resonance imaging detectable reporter molecules, which allows assessment at different time points. Methods:...